Recall Register

Food, drugs, devices › SCA Pharmaceuticals

Drug recall: FentaNYL 500 mcg/250 mL - Bupivacaine HCl 0.1% in 0.9% Sodium Chloride 250mL Bag, Injection for Epidural Use (fentaNYL C

FDA enforcement event 92737 · Class II · initiated 20 Jul 2023 · status Terminated · terminated 21 Sep 2023

DrugVoluntary: Firm initiated1 product recordWindsor, CT

FDA enforcement event 92737 is a drug recall by SCA Pharmaceuticals of Windsor, CT, initiated 20 Jul 2023 and classified Class II, with 1 product record.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 59% of the 281 drug enforcement events initiated in 2023 carry the same class.

Status: Terminated, terminated 21 Sep 2023. Initiation: voluntary: firm initiated. SCA Pharmaceuticals has 19 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

SCA Pharmaceuticals, Windsor, CT.

Reason for recall

"cGMP deviations: due to shipment of rejected units."

Distribution

"KY and NJ"

Product records

Recall numberProductQuantityClassStatusReport date
D-0945-2023FentaNYL 500 mcg/250 mL - Bupivacaine HCl 0.1% in 0.9% Sodium Chloride 250mL Bag, Injection for Epidural Use (fentaNYL Concentration - 2 mcg/mL), Rx Only, Single Dose Container, SCA Pharmaceuticals, 755 Rainbow Rd, Windsor, CT 06095, NDC# 70004-0253-40183 bagsClass IITerminated2 Aug 2023

Context

59%of 2023 drug events are Class II281 events that year
1product record in this eventfirm median: 1
19events on this register for the firm

Other enforcement events for SCA Pharmaceuticals

InitiatedProduct (first record)TypeClassRecords
10 Apr 2023Oxytocin 30 units added to 0.9% Sodium Chloride 500 mL, Rx Only, Single Dose Container, SCA Pharmaceuticals, Windsor, CTDrugClass III1
24 Feb 2023Fentanyl 1,500 mcg/30 mL syringe, Injection for Intravenous Use, Concentration = 50 mcg/mL, Preservative Free, Rx Only, DrugClass III1
25 Apr 2022Norepinephrine 8mg in 0.9% Sodium Chloride 250 mL bag, Rx only, SCA Pharmaceuticals Windsor, CT 06095, NDC 70004-078-40DrugClass II3
17 Dec 2020Atropine Sulfate Injection, 0.8 mg/2 mL (0.4 mg/mL), 2 mL Single Dose Syringe, Rx Only, SCA Pharmaceuticals, 755 RainbowDrugClass II32
20 Nov 2020Fentanyl, 250 mcg/ 5mL, Injection for IV or IM use, Rx only, SCA Pharmaceuticals, 8821 Knoedl Ct., Little Rock, AR 72205DrugClass III1
29 Jul 2020Heparin Sodium 2,500 units in 0.9% Sodium Chloride 500 mL, Single Dose Container, Rx Only Injection for Intravenous Use DrugClass I4
29 Jul 2020Heparin Sodium 5,000 units in 0.9% Sodium Chloride 1000 mL bag (5 units/mL), Rx only, SCA Pharmaceuticals 755 Rainbow RdDrugClass II1
16 Jun 2020Heparin Sodium 5,000 units in 0.9% Sodium Chloride 1000 mL bag (5 units/mL), Rx Only, SCA Pharmaceuticals 755 Rainbow RdDrugClass II1
29 Jun 2018Buffered Lidocaine 1% with Sodium Bicarbonate Injection for Local Anesthetic Use (Concentration=10 mg/mL) 0.25 mL Total DrugClass II1
7 Dec 2017Ephedrine sulfate 5 mg/mL in 0.9% Sodium Chloride 10 mL in Single Dose Syringe, Total Volume 10 mL, Rx only, SCA PharmacDrugClass II1

All 19 events for SCA Pharmaceuticals

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "cGMP deviations: due to shipment of rejected units."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "KY and NJ"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 21 Sep 2023. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.